U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115745) titled 'A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases' on Feb. 07.
Brief Summary: The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
Study Start Date: Aug. 23
Study Type: INTERVENTIONAL
Condition:
Refractory Autoimmune Diseases
Intervention:
GENETIC: BMS-986515
Specified dose on specified days
DRUG: Fludarabine
Specified dose on specified days
DRUG: Cyclophospham...